Summary:
A Phase 1, Double-Blind, Placebo-Controlled Study to
Evaluate the Safety, Tolerability and Pharmacokinetics of
Single Doses of AT-1501 in Healthy Adults and in Adults
with ALS
Qualified Participants Must:
• Healthy male and female subjects age 18 to 55
•
Be in good health based upon medical history, physical examination, vital signs, ECG and laboratory tests
Qualified Participants May Receive:
Compensation for time and travel